TABLE 1.
Baseline patient characteristics
| Patients (n) | 8 |
| Male sex, n (%) | 7 (88) |
| Age, years | 65.6 ± 11.2 |
| Comorbidity, n (%) | |
| Cardiovascular disease | 3 (38) |
| Asthma | 1 (13) |
| Neurological disease | 1 (13) |
| Malignancy | 2 (25) |
| Long‐term medication, n (%) | |
| Anti‐hypertensive drugs | 2 (25) |
| Statins | 3 (28) |
| Diabetes drugs | 1 (13) |
| Antiplatelet drugs | 2 (25) |
| Symptoms, n | |
| Fever | 6 |
| Cough | 5 |
| Dyspnoea | 2 |
| Headache | 2 |
| Other | 2 |
| Duration of COVID‐19 symptoms until death, days (range) | 15.5 (5–44) |
| Pulmonary embolism, n (%) | 3 (38) |
| Signs of RV dysfunction, n | |
| Histology | 0 |
| CTPA | |
| RV/LV > 1 | 2 |
| Enlarged pulmonary artery | 4 |
| Cause of death, n (%) | |
| COVID‐19 respiratory failure | 4 (50) |
| Multi‐organ failure | 2 (25) |
| Malignancy | 1 (12.5) |
| Neurological disease, not related to COVID‐19 | 1 (12.5) |
Abbreviations: COVID‐19, coronavirus disease 2019; CTPA, computed tomography pulmonary angiogram; LV, left ventricle; RV, right ventricle.